PHI with Ovarian cancer
How does this condition affect your private health insurance?
Eierstockkrebs, or ovarian cancer, is a malignant tumor originating in the ovaries, the female reproductive glands. It is often challenging to diagnose early due to its vague, non-specific symptoms, such as bloating, pelvic pain, difficulty eating, and urinary changes, which are easily mistaken for less serious conditions. There are several types, with epithelial ovarian cancer being the most common. Risk factors include age, family history, genetic mutations (e.g., BRCA1/2), and endometriosis. Treatment typically involves surgery to remove the tumor (debulking) followed by chemotherapy, and sometimes targeted therapies or immunotherapy. Prognosis largely depends on the stage at diagnosis.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several months for initial diagnosis and treatment (e.g., 6-9 months for surgery and chemotherapy).
Duration of Illness (Lifetime)
Long-term, often recurring, requiring ongoing surveillance and potential for multiple treatment courses over a lifetime.
Cost of Treatment (Initial)
Tens of thousands to hundreds of thousands of USD (e.g., $50,000 - $300,000+) depending on stage and complexity.
Cost of Treatment (Lifetime)
Hundreds of thousands to over a million USD, especially with recurrence, long-term surveillance, and ongoing therapies.
Mortality Rate
High, particularly if diagnosed at advanced stages (e.g., 5-year survival rate ~49% for all stages combined).
Risk of Secondary Damages
High, including physical (e.g., lymphedema, neuropathy, infertility, fatigue, surgical complications) and psychological (e.g., anxiety, depression, body image issues) impacts.
Probability of Full Recovery
Moderate to low, highly dependent on the stage at diagnosis (e.g., high for Stage I, significantly lower for Stage III/IV).
Underlying Disease Risk
Moderate, including genetic predispositions like BRCA1/2 mutations or Lynch syndrome, and conditions such as endometriosis, which increase the risk.